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 _____________________________________________________________________________________________________ 
This practice is based on reported experience from single 
institutions. 
In the first decade of the 21st century, local control using 
stereotactic radiotherapy or surgical resection of individual 
brain metastases has emerged as a clinically beneficial 
modality for highly selected patients. Whole brain 
radiotherapy is increasingly seen as a treatment provided in 
addition to this local control, or is held in reserve for salvage 
management should new or recurrent brain metastases 
develop at a later date – without RCT evidence supporting 
this approach (4,5,6).  
The majority of patients with brain metastases, however, are 
not suitable for stereotactic or surgical approaches and WBRT 
continues to be seen as the standard of care for this group, 
particularly if they are perceived to have a durable prognosis 
(5). Until the MRC QUARTZ trial was undertaken in non-small 
cell lung cancer (NSCLC) (Mulvenna et al 2016-in press), there 
were no sufficiently powered randomised controlled trials 
specifically addressing the utility of WBRT compared to 
supportive care (7).  
Although prophylactic cranial irradiation has enhanced 
overall survival and reduced incidence of brain metastases 
for patients with the exquisitely radiosensitive small cell 
variant of lung cancer, trials addressing this issue in NSCLC 
and Breast cancer have failed to accrue. This lack of high 
quality evidence added to the fear of neurocognitive decline 
remains a potential barrier to applying this technique to 
other solid tumours with a propensity for metastasising to the 
brain. 
 
Questions to address: 
Can we apply prognostic indices reliably to all solid tumour 
types? 
Do we really know which patients will benefit from WBRT, 
whether used as a sole palliative modality or as an adjunct to 
local (stereotactic or surgical) modalities?  
If so, how can we best use Image Guided radiotherapy to 
minimise long term neurocognitive impact? 
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Brain metastases (BM) develop in up to 30% of patients with 
cancer. There is marked heterogeneity in outcomes for 
patients with BM, and these outcomes vary not only by 
diagnosis, but also by diagnosis-specific prognostic factors; 
we should not treat all patients with brain metastases the 
same way, treatment should be individualized. 
Phase III randomized trials have shown that upfront whole 
brain radiotherapy (WBRT) may decrease brain recurrence 
both in terms of better local and improved distant brain 
tumour control rate, and that neurological death rate may be 
reduced in patients treated with WBRT + stereotactic 
radiosurgery (SRS), but no survival benefit is reached. The 
EORTC 22952-26001 study (Kocher M et al) shows that 
adjuvant WBRT fails to improve the duration of functional 
independence. 
The use of SRS in the treatment of multiple BM has increased 
dramatically during the past decade to avoid the 
neurocognitive dysfunction induced by WBRT. 
One of the biggest (1194 patients) multi-institutional 
prospective observational studies (JLGK0901, Yamamoto M et 
al and Watanabe S et al) including patients with multiple BM 
(even more than 10) have shown that SRS without WBRT in 
patients with five to ten BM is non-inferior to that in patients 
with two to four BM in terms of median OS (10,8 months for 
both groups), 1-year local recurrence (6,5% and 7%), with a 
very low incidence of side effects (less than 3%). They also 
concluded that carefully selected patients with 10 or more 
BM are not unfavourable candidates for SRS alone, having 
these patients a median survival time and neurological death-
free survival times comparables to the group with 9-10 BM; 
their results suggest also that even among patients 80 years 
and older, those with modified-RPA Class I+IIa or IIb disease 
are considered to be favourable candidates for more 
aggressive treatment of BM. 
SRS has been an option for limited (1-3) metastatic brain 
lesions, and nowadays the updated guidelines (for example, 
the NCCN panel) have recently added SRS as a primary 
treatment option for multiple (>3) metastatic lesions. 
The exclusive SRS approach for patients with multiple BM is 
mostly curative for each treated lesion, it can be repeated 
several times (the limits in terms of median cumulative dose 
to the normal brain must be explored), and WBRT remains an 
option as salvage treatment. 
Exclusive SRS with frequent magnetic resonance imaging-
based follow-ups (every 2-3 months) in order to salvage 
recurrent BM before symptomatic manifestations, should be 
routinely offered to selected patients as a treatment option 
to consider (Lester SC et al). Initial treatment with a 
combination of SRS and close clinical monitoring should be 
recommended as the preferred treatment strategy to better 
preserve learning and memory in good prognosis patients 
with newly diagnosed BM (Chang EL et al). 
The Lausanne University Hospital (CHUV) has created a brain 
metastases clinic to provide medical and radiation oncology, 
neurosurgical, and supportive services to this complex 
patient population. During the first 18 months, 250 cases 
were discussed, 55% of patients had more than one brain 
metastases, and focal treatments were proposed in 69% of 
treated cases (for 50% of them radiosurgery or fractionated 
stereotactic radiotherapy, FSRT). WBRT was proposed to only 
16% of patients (some of them as salvage therapy after 
sequential treatments with SRS). 
Higher BM burden (in terms of size and volume) and higher 
integral SRS dose to the brain are the main predictive factors 
for late toxicity after SRS. The cumulative neurocognitive 
effect of numerous SRS sessions remains unknown. In order to 
reduce the cumulative median dose to the brain, the SRS 
technique must be carefully chosen. 
At CHUV, we have performed a dosimetric comparison study 
in cases with multiple brain metastases (up to 10), comparing 
a radiosurgical planning (same dose and isodose prescription) 
with Gamma Knife (GK), CyberKnife (CK), VMAT and Helical 
Tomotherapy (HT). Gradient index was better with GK and CK 
(3.4 and 4.1, compared to 17.8 and 19), as well as PTV 
coverage (100% with GK and CK, compared to 97% with VMAT 
and 90% with HT); brain Dmean was lower with GK (3 Gy) and 
CK (2.66 Gy), compared to VMAT (6.4 Gy) and HT (6.72 Gy). 
SRS alone should be considered a routine treatment option in 
patients with multiple BM due to favourable neurocognitive 
outcomes, less risk of late side effects, without adversely 
affecting the patients performance status. 
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